About Amgen Astellas BioPharma
Amgen Astellas BioPharma is a company based in Chiyoda (Japan) founded in 2013 was acquired by Amgen in January 2020.. Amgen Astellas BioPharma operates in a competitive market with competitors including Portola Pharma, Alexion, argenx, MyoKardia and Cellino, among others.
- Headquarter Chiyoda, Japan
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Amgen Astellas BioPharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Amgen Astellas BioPharma
Amgen Astellas BioPharma has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Amgen. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Developer of pharmaceutical products for treating multiple diseases
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Amgen Astellas BioPharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Amgen Astellas BioPharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Amgen Astellas Biopharma Comparisons
Competitors of Amgen Astellas BioPharma
Amgen Astellas BioPharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Portola Pharma, Alexion, argenx, MyoKardia and Cellino, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for cardiovascular and autoimmune diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for rare and devastating diseases are developed by Alexion.
|
|
| domain | founded_year | HQ Location |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| domain | founded_year | HQ Location |
Specialized drugs are developed for genetic heart diseases.
|
|
| domain | founded_year | HQ Location |
Developer of autologous cell therapies
|
|
| domain | founded_year | HQ Location |
Provider of tools for the analysis of RNA structures
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Amgen Astellas Biopharma
Frequently Asked Questions about Amgen Astellas BioPharma
When was Amgen Astellas BioPharma founded?
Amgen Astellas BioPharma was founded in 2013.
Where is Amgen Astellas BioPharma located?
Amgen Astellas BioPharma is headquartered in Chiyoda, Japan. It is registered at Chiyoda, Tokyo, Japan.
What does Amgen Astellas BioPharma do?
Amgen Astellas BioPharma formed as a JV between Amgen and Astellas, a Tokyo based pharma company, for the co-development and commercialization of Amgens key late-stage pipeline candidates in Japan. The joint venture received the approval for Repatha (Evolocumab) in January 2016 from Japans MHLW and is expected to become a wholly owned subsidiary of Amgen by 2020. As of September 2017, the co-development pipeline between (Amgen Astellas and Astellas) had 3 products evolocumab treatment for hypercholesterolemia, romosozumab a treatment for osteoporosis, and blinatumomab, a treatment for oncology which are at different stage of development in Japan and abroad. There are also 3 other clinical candidates for malignant melanoma, migraine prevention and chronic heart failure in the pipeline of Amgen Astellas BioPharma at various stages of global and Japanese development.
Who are the top competitors of Amgen Astellas BioPharma?
Amgen Astellas BioPharma's top competitors include argenx, Kodiak Sciences and Tenaya Therapeutics.
Who are Amgen Astellas BioPharma's investors?
Amgen Astellas BioPharma has 1 investor. Key investors include Amgen.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.